This week, James is joined by George McBride, co-founder and COO of Clerkenwell Health a psychedelic-specialty clinical research organisation and site network headquartered in London. George is a commercial barrister turned drug policy reform advocate and entrepreneur. He's played in a key role in the campaign to legalise medical cannabis in the UK at the NGO Volteface before founding Europe’s leading cannabis advisory firm, Hanway Associates and industry conference Cannabis Europa. 
Learn more about Clerkenwell Health: <a href="https://www.clerkenwellhealth.com/">https://www.clerkenwellhealth.com/</a>
Apply to be a guest: <a href="https://www.thehealthtechpodcast.com/">www.thehealthtechpodcast.com</a>
Subscribe to Healthtech Pigeon 🐦: <a href="https://www.healthtechpigeon.com/">www.healthtechpigeon.com</a>
Get in touch with James: <a href="https://www.jamessomauroo.com/">www.jamessomauroo.com</a>
Learn more about SomX for your healthtech company at <a href="https://somx.health/">somx.health</a>

James Somauroo

#372 Breaking Barriers in Psychedelic Drug Research with George McBride founder of Clerkenwell Health

This week, James is joined by George McBride, co-founder and COO of Clerkenwell Health a psychedelic-specialty clinical research organisation and site network headquartered in London. George is a commercial barrister turned drug policy reform advocate and entrepreneur. He's played in a key role in the campaign to legalise medical cannabis in the UK at the [&hellip;]